papillary thyroid cancer glp 1 No Increased Risk for in Diabetic Patients Prescribed GLP-1 Medications Compared to Those Prescribed Insulin More Thyroid Cancers Found After

The FDA has issued a warning about serious safety risks linked to unapproved and compounded versions of GLP-1 receptor agonists, including semaglutide (the active ingredient in Ozempic and Wegovy)

& Hoso, M

Semaglutide acts like human glucagon-like peptide-1 (GLP-1), in that it increases insulin secretion which thereby increases sugar metabolism

[DOI] [PMC free article] [PubMed] [Google Scholar] [165].Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C, Pancreatic safety of incretin-based drugs--FDA and EMA assessment, The New England journal of medicine, 370 (2014) 794797

However, a considerable part of patients presents with unsatisfactory response in the long term